drugset / Trial / NCT00643604

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

NCT00643604

Phase 4 Terminated 7 enrolled United Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.

Timeline

Start
2008-03
Primary completion
2010-01
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified Intravenous